242 related articles for article (PubMed ID: 29046291)
1. Diabetic Kidney Disease.
Tong L; Adler SG
Clin J Am Soc Nephrol; 2018 Feb; 13(2):335-338. PubMed ID: 29046291
[No Abstract] [Full Text] [Related]
2. GLP-1 Receptor Agonists in Diabetic Kidney Disease.
Michos ED; Tuttle KR
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1578-1580. PubMed ID: 33849933
[No Abstract] [Full Text] [Related]
3. Transforming the Care of Patients with Diabetic Kidney Disease.
Brosius FC; Cherney D; Gee PO; Harris RC; Kliger AS; Tuttle KR; Quaggin SE;
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1590-1600. PubMed ID: 34103350
[TBL] [Abstract][Full Text] [Related]
4. Clinical manifestations and natural history of diabetic kidney disease.
Ritz E
Med Clin North Am; 2013 Jan; 97(1):19-29. PubMed ID: 23290727
[TBL] [Abstract][Full Text] [Related]
5. Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function".
Pugliese G; Penno G; Natali A; Barutta F; Di Paolo S; Reboldi G; Gesualdo L; De Nicola L;
Nutr Metab Cardiovasc Dis; 2019 Nov; 29(11):1127-1150. PubMed ID: 31586514
[TBL] [Abstract][Full Text] [Related]
6. Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases.
Bramlage P; Lanzinger S; van Mark G; Hess E; Fahrner S; Heyer CHJ; Friebe M; Seufert J; Danne T; Holl RW
Cardiovasc Diabetol; 2019 Mar; 18(1):33. PubMed ID: 30878037
[TBL] [Abstract][Full Text] [Related]
7. Effects of suspending ACE inhibitors and ARBs in advanced chronic kidney disease.
Díaz-Domínguez ME; Fernández-Lucas M; Gomis-Couto A; Ruiz-Roso G; Teruel JL; Quereda C
Nefrologia; 2012 May; 32(3):400-1. PubMed ID: 22592428
[No Abstract] [Full Text] [Related]
8. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
10. 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system.
Fernández-Juárez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Lahera V; Casas L; Oliva J;
Clin J Am Soc Nephrol; 2013 Nov; 8(11):1870-6. PubMed ID: 24135218
[TBL] [Abstract][Full Text] [Related]
11. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
Fried LF; Duckworth W; Zhang JH; O'Connor T; Brophy M; Emanuele N; Huang GD; McCullough PA; Palevsky PM; Seliger S; Warren SR; Peduzzi P;
Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
[TBL] [Abstract][Full Text] [Related]
12. Analysis from the EMPA-REG OUTCOME
Mayer GJ; Wanner C; Weir MR; Inzucchi SE; Koitka-Weber A; Hantel S; von Eynatten M; Zinman B; Cherney DZI
Kidney Int; 2019 Aug; 96(2):489-504. PubMed ID: 31142441
[TBL] [Abstract][Full Text] [Related]
13. Detecting and controlling diabetic nephropathy: what do we know?
Appel G
Cleve Clin J Med; 2013 Apr; 80(4):209-17. PubMed ID: 23547091
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological Management of Diabetic Nephropathy.
Papademetriou V; Alataki S; Stavropoulos K; Papadopoulos C; Bakogiannis K; Tsioufis K
Curr Vasc Pharmacol; 2020; 18(2):139-147. PubMed ID: 30961500
[TBL] [Abstract][Full Text] [Related]
15. Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Jin SM; Han KA; Yu JM; Sohn TS; Choi SH; Chung CH; Park IeB; Rhee EJ; Baik SH; Park TS; Lee IK; Ko SH; Hwang YC; Cha BS; Lee HW; Nam MS; Lee MK
Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2108-14. PubMed ID: 27493100
[TBL] [Abstract][Full Text] [Related]
16. [Prediction, screening and treatment of renal complications of diabetes].
Marre M; Larger E
Rev Prat; 2001 Oct; 51(16):1769-75. PubMed ID: 11795120
[TBL] [Abstract][Full Text] [Related]
17. Decrease mortality in type II diabetes mellitus: glycemic and renal function control.
Borghi C; Ventura F
J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e13-e15. PubMed ID: 29538138
[No Abstract] [Full Text] [Related]
18. Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy.
van der Sande NG; Dorresteijn JA; Visseren FL; Dwyer JP; Blankestijn PJ; van der Graaf Y; Heerspink HL
Diabetes Obes Metab; 2016 Nov; 18(11):1120-1127. PubMed ID: 27337598
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
Parving HH; Andersen S; Jacobsen P; Christensen PK; Rossing K; Hovind P; Rossing P; Tarnow L
Semin Nephrol; 2004 Mar; 24(2):147-57. PubMed ID: 15017527
[TBL] [Abstract][Full Text] [Related]
20. Quality of care in patients with diabetic kidney disease in Asia: The Joint Asia Diabetes Evaluation (JADE) Registry.
Luk AO; Li X; Zhang Y; Guo X; Jia W; Li W; Weng J; Yang W; Chan WB; Ozaki R; Tsang CC; Mukhopadhyay M; Ojha AK; Hong EG; Yoon KH; Sobrepena L; Toledo RM; Duran M; Sheu W; Q Do T; Nguyen TK; Ma RC; Kong AP; Chow CC; Tong PC; So WY; Chan JC;
Diabet Med; 2016 Sep; 33(9):1230-9. PubMed ID: 26511783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
